104 related articles for article (PubMed ID: 37188260)
1. Use of sotrovimab in vaccinated versus unvaccinated COVID-19 patients in a resource-limited emergency department during the omicron surge.
Nene RV; Santodomingo MA; Balog B; Martinez H; Murillo E; Tomaszewski CA; LaFree A
J Am Coll Emerg Physicians Open; 2023 Jun; 4(3):e12958. PubMed ID: 37188260
[TBL] [Abstract][Full Text] [Related]
2. Real-world effectiveness of early remdesivir and sotrovimab in the highest-risk COVID-19 outpatients during the Omicron surge.
Piccicacco N; Zeitler K; Ing A; Montero J; Faughn J; Silbert S; Kim K
J Antimicrob Chemother; 2022 Sep; 77(10):2693-2700. PubMed ID: 35913836
[TBL] [Abstract][Full Text] [Related]
3. Experience of the United Arab Emirates in the use of monoclonal antibody drug sotrovimab in high-risk vaccinated and unvaccinated patients with COVID-19: an observational cohort study.
Abdalateef S; Al Meheiri NM; Nassef M; Shorrab AA; Hashimi OAR; Allam S; Alnaqbi MS; Al-Rifai RH
BMJ Open; 2023 Jan; 13(1):e066095. PubMed ID: 36627160
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of sotrovimab for vaccinated or unvaccinated patients with mild-to-moderate COVID-19 in the omicron era.
Izumo T; Awano N; Kuse N; Sakamoto K; Takada K; Muto Y; Fujimoto K; Saiki A; Ito Y; Ota H; Inomata M
Drug Discov Ther; 2022 Jul; 16(3):124-127. PubMed ID: 35753770
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of Monoclonal Antibody Infusion Treatment During Delta (B.1.617.2) and Omicron (B.1.1.529) COVID 19 Variant Surges among Vaccinated and Unvaccinated Patients.
Ghazanfar H; Haider A; Gurjar H; Hernandez N; Jyala A; Bhatt T; Zeana C; Chilimuri S
Health Serv Insights; 2022; 15():11786329221127153. PubMed ID: 36186738
[TBL] [Abstract][Full Text] [Related]
6. Real-world Clinical Outcomes of Bebtelovimab and Sotrovimab Treatment of High-risk Persons With Coronavirus Disease 2019 During the Omicron Epoch.
Razonable RR; Tulledge-Scheitel SM; Hanson SN; Arndt RF; Speicher LL; Seville TA; Larsen JJ; Ganesh R; O'Horo JC
Open Forum Infect Dis; 2022 Oct; 9(10):ofac411. PubMed ID: 36213724
[TBL] [Abstract][Full Text] [Related]
7. Casirivimab/imdevimab treatment for outpatient COVID-19 during a SARS-CoV-2 B1.617.2 (Delta) surge at a community hospital.
Keshishian E; Kuge E; Memmott J; Hasenbalg P; Belford N; Matlock A; Schritter S; Agbayani G; Dietrich T; Santarelli A; Ashurst J
J Osteopath Med; 2022 Dec; 122(12):635-640. PubMed ID: 36123325
[TBL] [Abstract][Full Text] [Related]
8. A Quick Displacement of the SARS-CoV-2 variant Delta with Omicron: Unprecedented Spike in COVID-19 Cases Associated with Fewer Admissions and Comparable Upper Respiratory Viral Loads.
Fall A; Eldesouki RE; Sachithanandham J; Morris CP; Norton JM; Gaston DC; Forman M; Abdullah O; Gallagher N; Li M; Swanson NJ; Pekosz A; Klein EY; Mostafa HH
medRxiv; 2022 Jan; ():. PubMed ID: 35118480
[TBL] [Abstract][Full Text] [Related]
9. Assessment of unvaccinated and vaccinated patients with coronavirus disease 2019 (COVID-19) treated with monoclonal antibodies during the delta wave (July 1-August 20, 2021): a retrospective observational monocentric study.
Guo Y; Cowman K; Chang M; Bao H; Golia A; Mcsweeney T; Bard L; Simpson R; Andrews E; Pirofski LA; Nori P
BMC Infect Dis; 2022 Jul; 22(1):645. PubMed ID: 35896965
[TBL] [Abstract][Full Text] [Related]
10. Real-world effectiveness of sotrovimab and remdesivir for early treatment of high-risk hospitalized COVID-19 patients: A propensity score adjusted retrospective cohort study.
Koh LP; Chua SL; Vasoo S; Toh MPHS; Cutter JN; Nah PH; Leo YS; Tay JX; Young BE; Lye DC; Ong SWX
J Med Virol; 2023 Feb; 95(2):e28460. PubMed ID: 36602046
[TBL] [Abstract][Full Text] [Related]
11. Change in effectiveness of sotrovimab for preventing hospitalization and mortality for at-risk COVID-19 outpatients during an Omicron BA.1 and BA.1.1-predominant phase.
Aggarwal NR; Beaty LE; Bennett TD; Carlson NE; Mayer DA; Molina KC; Peers JL; Russell S; Wynia MK; Ginde AA
Int J Infect Dis; 2023 Mar; 128():310-317. PubMed ID: 36229005
[TBL] [Abstract][Full Text] [Related]
12. Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
Gupta A; Gonzalez-Rojas Y; Juarez E; Crespo Casal M; Moya J; Rodrigues Falci D; Sarkis E; Solis J; Zheng H; Scott N; Cathcart AL; Parra S; Sager JE; Austin D; Peppercorn A; Alexander E; Yeh WW; Brinson C; Aldinger M; Shapiro AE;
JAMA; 2022 Apr; 327(13):1236-1246. PubMed ID: 35285853
[TBL] [Abstract][Full Text] [Related]
13. Neutralizing Monoclonal Antibody Use and COVID-19 Infection Outcomes.
Ambrose N; Amin A; Anderson B; Barrera-Oro J; Bertagnolli M; Campion F; Chow D; Danan R; D'Arinzo L; Drews A; Erlandson K; Fitzgerald K; Garcia M; Gaspar FW; Gong C; Hanna G; Jones S; Lopansri B; Musser J; O'Horo J; Piantadosi S; Pritt B; Razonable RR; Roberts S; Sandmeyer S; Stein D; Vahidy F; Webb B; Yttri J
JAMA Netw Open; 2023 Apr; 6(4):e239694. PubMed ID: 37093599
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of bebtelovimab and sotrovimab treatment of solid organ transplant recipients with mild-to-moderate coronavirus disease 2019 during the Omicron epoch.
Yetmar ZA; Beam E; O'Horo JC; Seville MT; Brumble L; Ganesh R; Razonable RR
Transpl Infect Dis; 2022 Aug; 24(4):e13901. PubMed ID: 35848574
[TBL] [Abstract][Full Text] [Related]
15. Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19 During SARS-CoV-2 Delta and Omicron Waves in the USA.
Cheng MM; Reyes C; Satram S; Birch H; Gibbons DC; Drysdale M; Bell CF; Suyundikov A; Ding X; Maher MC; Yeh W; Telenti A; Corey L
Infect Dis Ther; 2023 Feb; 12(2):607-621. PubMed ID: 36629998
[TBL] [Abstract][Full Text] [Related]
16. Likelihood of infecting or getting infected with COVID-19 as a function of vaccination status, as investigated with a stochastic model for Aotearoa New Zealand for Delta and Omicron variants.
Watson LM
N Z Med J; 2022 Apr; 135():89-100. PubMed ID: 35728188
[TBL] [Abstract][Full Text] [Related]
17. Impact of chronic comorbidities on hospitalization, intensive care unit admission and death among adult vaccinated and unvaccinated COVID-19 confirmed cases during the Omicron wave.
Simard M; Boiteau V; Fortin É; Jean S; Rochette L; Trépanier PL; Gilca R
J Multimorb Comorb; 2023; 13():26335565231169567. PubMed ID: 37143739
[TBL] [Abstract][Full Text] [Related]
18. Sotrovimab use in Japanese inpatients with COVID-19: post-infusion adverse events.
Yoshida J; Shiraishi K; Tanaka M
BMC Infect Dis; 2022 Dec; 22(1):902. PubMed ID: 36461006
[TBL] [Abstract][Full Text] [Related]
19. Impact of Vaccination and Early Monoclonal Antibody Therapy on Coronavirus Disease 2019 Outcomes in Organ Transplant Recipients During the Omicron Wave.
Solera JT; Árbol BG; Alshahrani A; Bahinskaya I; Marks N; Humar A; Kumar D
Clin Infect Dis; 2022 Dec; 75(12):2193-2200. PubMed ID: 35445690
[TBL] [Abstract][Full Text] [Related]
20. Monoclonal Antibodies for Treatment of SARS-CoV-2 Infection During Pregnancy : A Cohort Study.
McCreary EK; Lemon L; Megli C; Oakes A; Seymour CW;
Ann Intern Med; 2022 Dec; 175(12):1707-1715. PubMed ID: 36375150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
